Autolus Therapeutics AUTL 深 沪
等待开盘 12-19 09:30:00 美东时间
1.58
+0.020
+1.28%
华盛通- 最 高1.62
- 今 开1.59
- 成交量 63.55万股
- 最 低 1.565
- 昨 收 1.56
- 总市值 4.20亿
- 52周最高 2.80
- 市盈率 静 --
- 换手率 0.24%
- 52周最低 1.105
- 委 比 14.41%
- 总股本 2.66亿
- 历史最高 53.24
- 量 比 0.52
- 振 幅 3.53%
- 历史最低 1.105
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
12-15 15:30
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
12-12 19:02
Autolus' Obe-cel Shows 95.5% Response In Pediatric High-Risk r/r B-ALL With Low Severe CRS And ICANS At ASH 2025
Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector
12-08 21:38
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
Autolus Therapeutics announced the appointment of Ryan Richardson to its Board of Directors. Richardson, with over 20 years of experience in healthcare and investment banking, previously served as Chief Strategy Officer at BioNTech and has played key roles in corporate development and strategic transactions. His expertise will support Autolus in expanding its CAR T therapy, obe-cel, into new indications and maximizing its growth potential.
12-01 12:00
Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?
U.K.'s NICE issues draft guidance recommending Autolus' Aucatzyl for adult r/r B-ALL, setting up imminent NHS launch and broader patient access.
11-26 01:37
Abercrombie & Fitch, Titan Machinery, Zoom Communications, Woodward And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones gaining around 100 points on Tuesday...
11-25 23:03
Autolus Wins UK Backing for New CAR-T Cancer Therapy AUCATZYL for Adults With Aggressive Leukemia
Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the National Institute for
11-25 17:07
Autolus Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
Autolus Therapeutics shares are trading lower after the company reported worse-...
11-12 21:48
Autolus Therapeutics Q3 EPS $(0.30) Misses $(0.22) Estimate, Sales $21.194M Miss $21.311M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.22) by 36.99 percent. This is a 3.23 percent increase over losses of $(0.31) per share
11-12 20:02
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
